Castle Biosciences

Expanding Diagnostic Menus Will Unlock Broad Clinical Potential

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

13 Feb 25

Updated

01 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

27.1%

-2.0%

27.1%

-2.0%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$35.639.8% overvalued

AnalystConsensusTarget Fair Value

Narrative

Updates8

Shared on 01 May 25

Fair value Decreased 8.75%

Shared on 23 Apr 25

Fair value Decreased 1.44%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 1.20%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

Fair value Increased 9.06%

AnalystConsensusTarget has decreased revenue growth from 0.6% to -1.3%.

AnalystConsensusTarget Fair Value

US$35.63

9.8% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

6.46%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$19.27m

Earnings '28

72.02x

PE Ratio '28

US$1.39b

Market Cap '28

US$1.39b

Market Cap '28

32.23m

No. shares '28

US$43.06

Share Price '28

US$43.06 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$35.37

Fair Value '25